MGRD Q1 2026 Earnings EPS Beat Surprises Revenue Data Absent BUSEP Q1 2026 Earnings 132 EPS Surprise Boosted by Solid Core Operations ALBT Q1 2026 Earnings Narrowed Losses Maintain Focus on Cell Therapy Pipeline BSAC Q1 2026 Earnings EPS Surpasses Estimates Shares Rally on Strong Performance EXP Q1 2026 Earnings Powerful EPS Beat Highlights Cost Discipline Amid Subdued Demand DORM Q1 2026 Earnings EPS Miss Weighs on Investor Sentiment